Please login to the form below

Not currently logged in
Email:
Password:

NGF

This page shows the latest NGF news and features for those working in and with pharma, biotech and healthcare.

FDA fast-tracks Pfizer and Lilly's tanezumab

FDA fast-tracks Pfizer and Lilly's tanezumab

Pfizer and Lilly have been in a three-horse race to bring the first NGF inhibitor to market. ... Prior to the many clinical setbacks, analysts had predicted NGF inhibitors could become an $11bn drug category.

Latest news

  • FDA halts study of Teva and Regeneron's pain drug fasinumab FDA halts study of Teva and Regeneron's pain drug fasinumab

    The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... Arthropathy has been seen before with NGF inhibitors - and caused the agency to

  • Takeda hands back rights to two Amgen drugs Takeda hands back rights to two Amgen drugs

    Last month however Sanofi said its fasinumab candidate had performed well in a phase II/III trial, raising hopes that NGF inhibition remains a valid drug target. ... Analysts have suggested that a successful NGF inhibitor could be a blockbuster as it

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Pfizer-partnered NGF inhibitor tanezumab for osteoarthritis pain, chronic lower back pain and cancer pain.

  • Regeneron says anti-NGF fasinumab works in pain Regeneron says anti-NGF fasinumab works in pain

    Regeneron says anti-NGF fasinumab works in pain. Clinical trial shows promise for opioid alternative. ... NGF has been targeted for years because it operates at the heart of multiple pain-signalling pathways.

  • J&J drops NGF blocker fulranumab J&J drops NGF blocker fulranumab

    J&J drops NGF blocker fulranumab. Says decision to return rights to Amgen based on “ strategic portfolio prioritisation”. ... Johnson &Johnson has returned the rights to fulranumab to Amgen, raising another question mark over the role of nerve growth

More from news
Approximately 4 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics